Expertise in
5
conditions

Dr. Ahmed O. Kaseb

Oncology
UT MD Anderson Cancer Center
1515 Holcombe Blvd, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
5
conditions
UT MD Anderson Cancer Center
1515 Holcombe Blvd, 
Houston, TX 

Overview

Ahmed Kaseb is an Oncologist practicing medicine in Houston, Texas.

Dr. Kaseb is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Liver Cancer, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Disease, and Hepatectomy.

He is actively involved in clinical research, co-authoring 249 peer reviewed articles and participating in 10 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma
A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma
Enrollment Status: Recruiting
Publish Date: March 06, 2026
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein
Study Phase: Phase 1/Phase 2
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Genetic
Study Phase: Phase 1
An Open-Label, Phase II, Pre-Operative Study of Atezolizumab Plus Bevacizumab for Resectable Hepatocellular Carcinoma
An Open-Label, Phase II, Pre-Operative Study of Atezolizumab Plus Bevacizumab for Resectable Hepatocellular Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Biological, Procedure
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Phase II Study of Pembrolizumab (MK-3475) in Hepatitis C Virus Positive and Negative Subjects With Advanced Hepatocellular Carcinoma Who Progressed on or Were Intolerant to First-Line Systemic Therapy
A Phase II Study of Pembrolizumab (MK-3475) in Hepatitis C Virus Positive and Negative Subjects With Advanced Hepatocellular Carcinoma Who Progressed on or Were Intolerant to First-Line Systemic Therapy
Enrollment Status: Completed
Publish Date: July 15, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Elbasvir/Grazoprevir, Pembrolizumab, Ribavirin
Study Phase: Phase 2
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Navitoclax, Sorafenib, Sorafenib Tosylate
Study Phase: Phase 1
An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable (HCC)
An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable (HCC)
Enrollment Status: Completed
Publish Date: July 10, 2023
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Enrollment Status: Completed
Publish Date: December 30, 2021
Intervention Type: Other, Radiation, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

249 Total Publications

Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90Y Radioembolization with Immunotherapy in HCC.
Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90Y Radioembolization with Immunotherapy in HCC.
Journal: Radiology
Published: September 01, 2026
Similar Doctors
Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Office

1400 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.3 miles away)
713-792-2813
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist practicing medicine in Houston, Texas. Dr. Kantarjian is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Splenectomy.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-8850
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neeta Somaiah is an Oncologist practicing medicine in Houston, Texas. Dr. Somaiah is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Hepato-Pancreato-Biliary Surgery.

Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-2860
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luis Fayad is an Oncologist practicing medicine in Houston, Texas. Dr. Fayad is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Ahmed O. Kaseb

How do I make an appointment with Dr. Ahmed O. Kaseb?

You can book an appointment with Dr. Ahmed O. Kaseb by calling their office at 713-792-2121. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ahmed O. Kaseb a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ahmed O. Kaseb is classified as an Elite expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ahmed O. Kaseb specialize in?

While Dr. Ahmed O. Kaseb is a Oncology, they have specific expertise in Liver Cancer, Fibrolamellar Carcinoma, and Cholangiocarcinoma (Bile Duct Cancer). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ahmed O. Kaseb participate in research or clinical trials?

Yes. Dr. Ahmed O. Kaseb has published 249 articles and abstracts on conditions like Liver Cancer. You can view a list of Dr. Ahmed O. Kaseb's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ahmed O. Kaseb accept my insurance?

Dr. Ahmed O. Kaseb accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 713-792-2121 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaseb's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile